ExodusPoint Capital Management LP Takes Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

ExodusPoint Capital Management LP bought a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 69,277 shares of the company's stock, valued at approximately $322,000.

A number of other institutional investors have also added to or reduced their stakes in GDRX. Charles Schwab Investment Management Inc. raised its holdings in GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company's stock worth $3,332,000 after buying an additional 26,262 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of GoodRx in the 3rd quarter worth about $73,000. Barclays PLC lifted its position in GoodRx by 1,316.1% in the 3rd quarter. Barclays PLC now owns 140,113 shares of the company's stock valued at $973,000 after acquiring an additional 130,219 shares in the last quarter. Geode Capital Management LLC boosted its stake in GoodRx by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company's stock valued at $6,823,000 after purchasing an additional 58,610 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in GoodRx during the 3rd quarter worth approximately $85,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Stock Performance

NASDAQ GDRX traded up $0.04 on Friday, hitting $4.49. 545,787 shares of the stock traded hands, compared to its average volume of 1,378,990. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -149.67, a PEG ratio of 2.46 and a beta of 1.25. The business's fifty day moving average is $4.62 and its two-hundred day moving average is $5.00. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. GoodRx Holdings, Inc. has a 12 month low of $3.82 and a 12 month high of $9.26.

Analyst Ratings Changes

GDRX has been the topic of a number of recent research reports. Citigroup dropped their target price on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a report on Friday, January 10th. KeyCorp cut their price objective on shares of GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Wells Fargo & Company lowered their target price on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Truist Financial cut their price target on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, GoodRx presently has an average rating of "Moderate Buy" and a consensus price target of $7.93.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.